Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
Shattuck Labs (NASDAQ: STTK) will report its Q3 2022 financial results on November 8, 2022, at 4:30 p.m. ET, during a conference call led by CEO Taylor Schreiber. Experts anticipate insights into the company's innovative bi-functional fusion proteins aimed at treating cancer and autoimmune diseases. Currently, the SL-172154 and SL-279252 programs are in Phase 1 trials, utilizing Shattuck's proprietary ARC® platform. Investors can listen to the live webcast on Shattuck's website.
- Ongoing Phase 1 trials for SL-172154 and SL-279252 targeting cancer treatment.
- Innovative approach using ARC® platform to tackle autoimmune diseases.
- None.
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.
Title: Shattuck Labs Third Quarter 2022 Earnings Conference Call
Speakers: Taylor Schreiber, CEO; Lini Pandite, CMO; Andrew Neill, CFO
Date & Time: Tuesday, November 8, 2022 at 4:30 p.m. ET
Dial-in Details: Toll-Free Dial-In Number: (888) 440-4368; Toll Dial-In Number: (646) 960-0856; Conference ID: 5023003
To listen to the live webcast, please visit the Investor Relations page of the Shattuck Labs website here. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.
A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. A second product candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in solid tumors or lymphomas. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
When will Shattuck Labs release its Q3 2022 earnings?
What are the key products being evaluated by Shattuck Labs?
Who will speak during the Shattuck Labs earnings call?
